徐真谛;李润芝;李元宽;杨小生;

• 1:重庆市垫江县中医院检验科
• 2:重庆市垫江县中医院药学部

摘要(Abstract)：

目的探讨IFN-γ诱导非小细胞肺癌A549细胞表达PD-L1的分子机制。方法 IFN-γ刺激体外培养的非小细胞肺癌A549细胞,或加入信号通路抑制剂预先孵育1 h后再行刺激,流式细胞术检测PD-L1的表达水平。分选CD~+_3 T细胞与A549细胞共培养,检测CD~+_3 T细胞的增殖情况。结果与未刺激组A549细胞表达的PD-L1水平[(39.6±5.8)%]比较,IFN-γ刺激的A549细胞显著上调PD-L1的蛋白水平[(94.3±4.9)%],二者比较差异有统计学意义(P<0.01)。加入STAT1抑制剂后,IFN-γ上调PD-L1的效果受到显著抑制,差异有统计学意义(P<0.01)。而STAT3抑制剂、STAT5抑制剂、STAT6抑制剂和NF-κB抑制剂无明显影响。与未刺激组比较,IFN-γ刺激组A549细胞能够显著抑制CD~+_3 T细胞的增殖能力。结论 IFN-γ可通过STAT1信号诱导A549细胞上调PD-L1的表达,从而促进肺癌的免疫逃逸。

关键词(KeyWords)： IFN-γ;PD-L1;STAT1信号

Abstract:

Keywords:

基金项目(Foundation): 重庆市渝中区科委资助项目(编号:20180165)

作者(Author): 徐真谛;李润芝;李元宽;杨小生;

Email:

DOI:

参考文献(References)：

• 1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin,2018,68:394-424.
• 2 Salehi-rad R,Li R,Paul MK,et al.The Biology of Lung Cancer:Development of More Effective Methods for Prevention,Diagnosis,and Treatment.Clin Chest Med,2020,41:25-38.
• 3 Zhang H,Chen J.Current status and future directions of cancer immunotherapy.J Cancer,2018,9:1773-1781.
• 4 Inoue H,Okamoto I.Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage Ⅲ Non-Small Cell Lung Cancer:Emerging Mechanisms and Perspectives.Lung Cancer (Auckl),2019,10:161-170.
• 5 Cavazzoni A,Digiacomo G,Alfieri R,et al.Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer.Cancers (Basel),2020,12:E666.
• 6 Dong W,Wu X,Ma S,et al.The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.Cancer Discov,2019,9:1422-1437.
• 7 Buttner R,Gosney JR,Skov BG,et al.Programmed Death-Ligand 1 immunohistochemistry testing:a review of analytical assays and clinical implementation in Non-Small-Cell lung cancer.J Clin Oncol,2017,35:3867-3876.
• 8 Horn L,Gettinger SN,Gordon MS,et al.Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer:final results from a phase I study.Eur J Cancer,2018,101:201-209.
• 9 Greten FR,Grivennikov SI.Inflammation and Cancer:Triggers,Mechanisms,and Consequences.Immunity,2019,51:27-41.
• 10 Hsu PC,Jablons DM,Yang CT,et al.Epidermal Growth Factor Receptor (EGFR) Pathway,Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).Int J Mol Sci,2019,20:E3821.
• 11 Bassanelli M,Sioletic S,Martini M,et al.Heterogeneity of PD-L1 expression and relationship with biology of NSCLC.Anticancer Res,2018,38:3789-3796.
• 12 Davick JJ,Frierson HF,Smolkin M,et al.PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas:a pathologic review of 165 cases.Hum Pathol,2018,81:184-191.
• 13 Ren MIN,Dai BO,Kong YUN-YI,et al.PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.Histopathology,2018,73:386-396.
• 14 Kim A,Lee SJ,Kim YK,et al.Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.Sci Rep,2017,7:11671.
• 15 Wang TT,Zhao YL,Peng LS,et al.Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway.Gut,2017,66:1900-1911.
• 16 Zou W,Wolchok JD,Chen L.PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy:Mechanisms,response biomarkers,and combinations.Sci Transl Med,2016,8:328rv4.
• 17 Wang X,Yang L,Huang F,et al.Inflammatory cytokines IL-17 and TNF-alpha up-regulate PD-L1 expression in human prostate and colon cancer cells.Immunol Lett,2017,184:7-14.
• 18 Concha-benavente F,Srivastava RM,Trivedi S,et al.Identification of the Cell-Intrinsic and -Extrinsic pathways downstream of EGFR and IFN gamma that induce PD-L1 expression in head and neck cancer.Cancer Res,2016,76:1031-1043.
• 19 Gao Y,Yang JJ,Cai YX,et al.IFN-gamma mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.International Journal of Cancer,2018,143:931-943.
• 20 Xue W,Li W,Zhang T,et al.Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression:possible involvement of an IFN-γ-associated JAK-STAT pathway.Onco Targets Ther,2019,12:2079-2088.
• 21 Kim WH,An HJ,Kim JY,et al.Apamin inhibits TNF-α- and IFN-γ-induced inflammatory cytokines and chemokines via suppressions of NF-κB signaling pathway and STAT in human keratinocytes.Pharmacol Rep,2017,69:1030-1035.
• 22 Shi Y.Regulatory mechanisms of PD-L1 expression in cancer cells.Cancer Immunol Immunother,2018,67:1481-1489.
• 23 Lv Y,Zhao Y,Wang X,et al.Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway.J Immunother Cancer,2019,7:54.
• 24 赵慧慧，杜泽涛，渠冉，等.卵巢癌免疫活化的研究进展.河北医药，2019,41:273-277.